NCT07468162

Brief Summary

Patients were enrolled according to predefined inclusion and exclusion criteria. Following surgical admission, standard monitoring was initiated, including continuous assessment of heart rate, blood pressure, electrocardiogram (ECG), and peripheral capillary oxygen saturation (SpO₂). A peripheral intravenous line was established. Bispectral index (BIS) monitoring was performed continuously using a BIS monitor to assess frontal lobe electroencephalographic activity. Based on the type of surgical procedure, regional nerve block was administered. Upon confirmation of adequate block efficacy, patients were assigned to treatment groups according to sealed envelope randomization, and corresponding intravenous sedative regimens were initiated. Sedative induction agents were administered as follows: Group A received remimazolam at 0.08 mg/kg; Group B received dexmedetomidine at 1 μg/kg over 10 minutes; Group C received midazolam at 0.05 mg/kg. Maintenance infusions were as follows: Group A received remimazolam at 1 mg/kg·h; Group B received dexmedetomidine at 0.2-0.7 μg/kg·h; for Group C, if consciousness was not sufficiently suppressed with the initial dose, midazolam was supplemented in increments of 0.01 mg/kg, not exceeding a total dose of 0.1 mg/kg. Following induction, sedation depth was assessed every 2 minutes using the Observer's Assessment of Alertness/Sedation (OAA/S) scale, with auditory stimulation applied every 30 seconds until the patient no longer responded. The time to loss of response to auditory stimuli and the time to loss of consciousness were recorded. Surgical intervention was then performed. Ten minutes prior to anticipated completion of surgery, sedative infusion was discontinued. Sedation depth was reassessed every 2 minutes using the OAA/S scale, with repeated auditory stimulation every 30 seconds to determine the time to return of response and time to recovery of consciousness. If the patient had not achieved an OAA/S score of 5 within 30 minutes after discontinuation of sedation, flumazenil was administered as a reversal agent. Once the OAA/S score reached 5 or spontaneous responses to auditory stimuli were observed-indicating transition back to a responsive state-and complete electroencephalographic data had been collected, no further intervention was required.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
48

participants targeted

Target at P25-P50 for all trials

Timeline
21mo left

Started Mar 2026

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress4%
Mar 2026Jan 2028

First Submitted

Initial submission to the registry

January 8, 2026

Completed
2 months until next milestone

First Posted

Study publicly available on registry

March 12, 2026

Completed
8 days until next milestone

Study Start

First participant enrolled

March 20, 2026

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 12, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 12, 2028

Last Updated

March 12, 2026

Status Verified

March 1, 2026

Enrollment Period

1.8 years

First QC Date

January 8, 2026

Last Update Submit

March 9, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Electroencephalogram changes during the perioperative period

    Power changes in α and β bands of electroencephalogram during the perioperative period

    From the date of random grouping until the end of the surgery

Study Arms (3)

sedation of remimazolam

Electroencephalogram changes under moderate deep sedation induced by remimazolam

Other: After the use of sedative drugs, the changes in the electroencephalogram (EEG) spectrum were observed with an EEG monitor

sedation of dexmedetomidine

Electroencephalogram changes under moderate deep sedation induced by dexmedetomidine

Other: After the use of sedative drugs, the changes in the electroencephalogram (EEG) spectrum were observed with an EEG monitor

sedation of midazolam

Electroencephalogram changes under moderate deep sedation induced by midazolam

Other: After the use of sedative drugs, the changes in the electroencephalogram (EEG) spectrum were observed with an EEG monitor

Interventions

Electroencephalogram changes under moderate deep sedation

sedation of dexmedetomidinesedation of midazolamsedation of remimazolam

Eligibility Criteria

Age20 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Patients undergoing elective orthopedic surgery under nerve block combined with intravenous anesthesia

You may qualify if:

  • Age: 20 - 60 years old. BMI: 18 ≤ BMI ≤ 24 kg/m2. Right-handed. ASA classification: I - II. Patients scheduled for extremity surgery of upper and lower limbs and undergoing nerve block, those who understand and sign the informed consent form, and those receiving non-endotracheal general anesthesia with remimazolam or dexmedetomidine or midazolam, with Mallampati classification: I - II.

You may not qualify if:

  • Skin infection at the site of nerve block puncture; history of smoking and alcohol abuse, history of brain surgery, history of cerebral infarction, mental and neurological disorders (MMSE \< 18, 3D-CAM positive), history of taking any psychotropic or opioid drugs within 2 weeks, hearing impairment, cardiovascular disease, expected difficulty in airway management or sleep apnea syndrome, drug (including those with a history of allergic reaction to the test drug or contraindications for use) or food allergies, pregnant or lactating patients, patients or family members who refuse to participate, and those who refuse to undergo nerve block.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (5)

  • Schuttler J, Eisenried A, Lerch M, Fechner J, Jeleazcov C, Ihmsen H. Pharmacokinetics and Pharmacodynamics of Remimazolam (CNS 7056) after Continuous Infusion in Healthy Male Volunteers: Part I. Pharmacokinetics and Clinical Pharmacodynamics. Anesthesiology. 2020 Apr;132(4):636-651. doi: 10.1097/ALN.0000000000003103.

  • Zhang H, Zhou QQ, Chen H, Hu XQ, Li WG, Bai Y, Han JX, Wang Y, Liang ZH, Chen D, Cong FY, Yan JQ, Li XL. The applied principles of EEG analysis methods in neuroscience and clinical neurology. Mil Med Res. 2023 Dec 19;10(1):67. doi: 10.1186/s40779-023-00502-7.

  • Schartner M, Seth A, Noirhomme Q, Boly M, Bruno MA, Laureys S, Barrett A. Complexity of Multi-Dimensional Spontaneous EEG Decreases during Propofol Induced General Anaesthesia. PLoS One. 2015 Aug 7;10(8):e0133532. doi: 10.1371/journal.pone.0133532. eCollection 2015.

  • Valizadeh SA, Riener R, Elmer S, Jancke L. Decrypting the electrophysiological individuality of the human brain: Identification of individuals based on resting-state EEG activity. Neuroimage. 2019 Aug 15;197:470-481. doi: 10.1016/j.neuroimage.2019.04.005. Epub 2019 Apr 9.

  • White-Dzuro GA, Du A, Brown EN, Akeju O, Peterfreund RA. The Effect of Midazolam Induction on Frontal Electroencephalogram Power. Anesth Analg. 2025 Nov 1;141(5):1185-1187. doi: 10.1213/ANE.0000000000007556. Epub 2025 May 23. No abstract available.

Central Study Contacts

weiliu Zhu, Master

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

January 8, 2026

First Posted

March 12, 2026

Study Start

March 20, 2026

Primary Completion (Estimated)

January 12, 2028

Study Completion (Estimated)

January 12, 2028

Last Updated

March 12, 2026

Record last verified: 2026-03